Results 91 to 100 of about 5,265 (145)

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C

Journal of Rawalpindi Medical College, 2017
Background:To determine the effectiveness of sofosbuvir plus ribavirin in terms of frequency of negative qualitative PCR at 2nd week of treatment in chronic hepatitis C patients with genotype 3.
Aqsa Naseer
doaj  

Hepatitis E Virus Drug Development

Viruses, 2019
Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in ...
Volker Kinast, Thomas L Burkard, Daniel Todt, Eike Steinmann   +3 more
doaj   +1 more source

Pooled risk ratio of sustained virological response at week 12 after the end of treatment between sofosbuvir plus ledipasvir with ribavirin and sofosbuvir plus ledipasvir.

, 2018
Pooled risk ratio of sustained virological response at week 12 after the end of treatment between sofosbuvir plus ledipasvir with ribavirin and sofosbuvir plus ledipasvir.
Thunyarat Anothaisintawee (840641), Yot Teerawattananon (180232), Ammarin Thakkinstian (840643), Thanthima Suwanthawornkul (840640), Abhasnee Sobhonslidsuk (840642)   +4 more
core   +1 more source

The SVR12 rates of patients treated with ledipasvir and sofosbuvir.

, 2018
The SVR12 rates of patients treated with ledipasvir and sofosbuvir.
Takeshi Kure (5328974), Tsutomu Tamai (496424), Kazuaki Tabu (496423), Kohei Oda (496422), Takeshi Hori (166759), Akihiro Moriuchi (496425), Masafumi Hashiguchi (5328965), Yukiko Inada (5328971), Kotaro Kumagai (496421), Hirofumi Uto (496418), Yasunari Hiramine (5328956), Seiichi Mawatari (496417), Kunio Fujisaki (5328962), Oki Taniyama (5328968), Sho Ijuin (5328953), Akio Ido (496419), Ai Kasai (5328959)   +16 more
core   +1 more source

Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial

Acta Medica Indonesiana
Background: Patients with chronic kidney disease undergoing hemodialysis are at risk of hepatitis C virus exposure due to nosocomial transmission and the duration of hemodialysis.
Andri Sanityoso Sulaiman, Pringgodigdo Nugroho, Muhammad Begawan Bestari, Afiatin Afiatin, Fardhah Akil, Akhyar Albaar, Hery Djagat Purnomo, Dwi Lestari, Triyanta Yuli Pramana, Agung Susanto, Desti Rachmani, Lawrence Ho Khek-Yu   +11 more
doaj   +4 more sources

A UPLC-MS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF SOFOSBUVIR FROM HUMAN PLASMA

, 2016
Objective: The present work aimed to develop a simple, rapid, specific and precise ultra-performance liquid chromatography-tandem mass spectrophotometric (LC–MS/MS) validated method for quantification of sofosbuvir and internal standard (ISTD) Sofosbuvir-
B. Rajkamal, Darshan Bhatt
core   +1 more source

Relationship between PPP-adjusted price, GDP per capita, and estimated market size for sofosbuvir and ledipasvir/sofosbuvir.

, 2016
Fig 2 shows the relationship between PPP-adjusted price (y-axis), GDP per capita (USD PPP) (x-axis), and estimated market size (circle size) for (A) sofosbuvir and (B) ledipasvir/sofosbuvir.
Peter Beyer (21528), Kees de Joncheere (3166164), Stefan Wiktor (3166158), Kiu Tay-Teo (3166161), Swathi Iyengar (3166167), Sabine Vogler (3131850), Suzanne Hill (160643)   +6 more
core   +1 more source

Curing of chronic hepatitis C combined with coronavirus disease 2019 in a couple over 85 years old: a case series study

Frontiers in Microbiology
IntroductionData on the management of patients aged more than 85 years with chronic hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequential infections are lacking.MethodsThe current study described the ...
Qing-Lei Zeng, Xue-Yan Lv, Ru-Yue Chen, Ya-Jie Pan   +3 more
doaj   +1 more source

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C

, 2017
Objectives: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection.
Hemstreet, Brian, Chahine, Elias, Sucher, Allana J., Sucher, Allana, Chahine, Elias B., Hemstreet, Brian A.   +5 more
core   +1 more source

Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity

, 2020
Sofosbuvir, the oral direct-acting antiviral, is a medication, which used as the effective treatment for hepatitis C infection. Although sofosbuvir thought to have few adverse-effects, there have been some experiences of serious drug-induced ...
Yousefsani, B.S., Pourahmad, J., Nabavi, N.   +2 more
core